133 related articles for article (PubMed ID: 35583632)
1. Serine-Arginine Protein Kinase 1 (SRPK1): a systematic review of its multimodal role in oncogenesis.
Duggan WP; O'Connell E; Prehn JHM; Burke JP
Mol Cell Biochem; 2022 Oct; 477(10):2451-2467. PubMed ID: 35583632
[TBL] [Abstract][Full Text] [Related]
2. Serine-Arginine Protein Kinase 1 (SRPK1) as a Prognostic Factor and Potential Therapeutic Target in Cancer: Current Evidence and Future Perspectives.
Nikas IP; Themistocleous SC; Paschou SA; Tsamis KI; Ryu HS
Cells; 2019 Dec; 9(1):. PubMed ID: 31861708
[TBL] [Abstract][Full Text] [Related]
3. Knockdown of Serine-Arginine Protein Kinase 1 Inhibits the Growth and Migration in Renal Cell Carcinoma Cells.
Han X; Yang J; Jia Z; Wei P; Zhang H; Lv W; Sun J; Huo Q
Oncol Res; 2017 Mar; 25(3):389-395. PubMed ID: 27662590
[TBL] [Abstract][Full Text] [Related]
4. The crucial role of SRPK1 in TGF-β-induced proliferation and apoptosis in the esophageal squamous cell carcinomas.
Ren G; Sheng L; Liu H; Sun Y; An Y; Li Y
Med Oncol; 2015 Jul; 32(7):209. PubMed ID: 26099172
[TBL] [Abstract][Full Text] [Related]
5. MiR-659-3p inhibits osteosarcoma progression and metastasis by inhibiting cell proliferation and invasion via targeting SRPK1.
Gong Y; Wei ZR
BMC Cancer; 2022 Aug; 22(1):934. PubMed ID: 36038837
[TBL] [Abstract][Full Text] [Related]
6. SRPK1 regulates RNA binding in a pre-spliceosomal complex using a catalytic bypass mechanism.
Aubol BE; Adams JA
FEBS J; 2022 Dec; 289(23):7428-7445. PubMed ID: 35730996
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of serine/arginine-rich protein kinase-1 (SRPK1) prevents cholangiocarcinoma cells induced angiogenesis.
Supradit K; Boonsri B; Duangdara J; Thitiphatphuvanon T; Suriyonplengsaeng C; Kangsamaksin T; Janvilisri T; Tohtong R; Yacqub-Usman K; Grabowska AM; Bates DO; Wongprasert K
Toxicol In Vitro; 2022 Aug; 82():105385. PubMed ID: 35568131
[TBL] [Abstract][Full Text] [Related]
8. Increased expression of SRPK1 (serine/arginine-rich protein-specific kinase 1) is associated with progression and unfavorable prognosis in cervical squamous cell carcinoma.
Dong Z; Chang X; Xie L; Wang Y; Hou Y
Bioengineered; 2022 Mar; 13(3):6100-6112. PubMed ID: 35192432
[TBL] [Abstract][Full Text] [Related]
9. Identification of hot spot residues on serine-arginine protein kinase-1 by molecular dynamics simulation studies.
Chandra A; Goyal N; Qamar I; Singh N
J Biomol Struct Dyn; 2021 Mar; 39(5):1579-1587. PubMed ID: 32093544
[TBL] [Abstract][Full Text] [Related]
10. The many faces of SRPK1.
Bullock N; Oltean S
J Pathol; 2017 Mar; 241(4):437-440. PubMed ID: 27859253
[TBL] [Abstract][Full Text] [Related]
11. Intra-domain Cross-talk Regulates Serine-arginine Protein Kinase 1-dependent Phosphorylation and Splicing Function of Transformer 2β1.
Jamros MA; Aubol BE; Keshwani MM; Zhang Z; Stamm S; Adams JA
J Biol Chem; 2015 Jul; 290(28):17269-81. PubMed ID: 26013829
[TBL] [Abstract][Full Text] [Related]
12. SRPK1 contributes to malignancy of hepatocellular carcinoma through a possible mechanism involving PI3K/Akt.
Zhou B; Li Y; Deng Q; Wang H; Wang Y; Cai B; Han ZG
Mol Cell Biochem; 2013 Jul; 379(1-2):191-9. PubMed ID: 23644876
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-1296 inhibits metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by targeting SRPK1-mediated PI3K/AKT pathway.
Xu Q; Liu X; Liu Z; Zhou Z; Wang Y; Tu J; Li L; Bao H; Yang L; Tu K
Mol Cancer; 2017 Jun; 16(1):103. PubMed ID: 28606154
[TBL] [Abstract][Full Text] [Related]
14. SRPK1 and Clk/Sty protein kinases show distinct substrate specificities for serine/arginine-rich splicing factors.
Colwill K; Feng LL; Yeakley JM; Gish GD; Cáceres JF; Pawson T; Fu XD
J Biol Chem; 1996 Oct; 271(40):24569-75. PubMed ID: 8798720
[TBL] [Abstract][Full Text] [Related]
15. Targeting alternative splicing as a new cancer immunotherapy-phosphorylation of serine arginine-rich splicing factor (SRSF1) by SR protein kinase 1 (SRPK1) regulates alternative splicing of PD1 to generate a soluble antagonistic isoform that prevents T cell exhaustion.
Wahid M; Pratoomthai B; Egbuniwe IU; Evans HR; Babaei-Jadidi R; Amartey JO; Erdelyi V; Yacqub-Usman K; Jackson AM; Morris JC; Patel PM; Bates DO
Cancer Immunol Immunother; 2023 Dec; 72(12):4001-4014. PubMed ID: 37973660
[TBL] [Abstract][Full Text] [Related]
16. Serine-arginine-rich protein kinase-1 inhibition for the treatment of diabetic retinopathy.
Malhi NK; Allen CL; Stewart E; Horton KL; Riu F; Batson J; Amoaku W; Morris JC; Arkill KP; Bates DO
Am J Physiol Heart Circ Physiol; 2022 Jun; 322(6):H1014-H1027. PubMed ID: 35302878
[TBL] [Abstract][Full Text] [Related]
17. Serine-arginine protein kinase 1 overexpression is associated with tumorigenic imbalance in mitogen-activated protein kinase pathways in breast, colonic, and pancreatic carcinomas.
Hayes GM; Carrigan PE; Miller LJ
Cancer Res; 2007 Mar; 67(5):2072-80. PubMed ID: 17332336
[TBL] [Abstract][Full Text] [Related]
18. Serine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer.
Mavrou A; Brakspear K; Hamdollah-Zadeh M; Damodaran G; Babaei-Jadidi R; Oxley J; Gillatt DA; Ladomery MR; Harper SJ; Bates DO; Oltean S
Oncogene; 2015 Aug; 34(33):4311-9. PubMed ID: 25381816
[TBL] [Abstract][Full Text] [Related]
19. SRPK1 gene silencing promotes vascular smooth muscle cell proliferation and vascular remodeling via inhibition of the PI3K/Akt signaling pathway in a rat model of intracranial aneurysms.
Li XG; Wang YB
CNS Neurosci Ther; 2019 Feb; 25(2):233-244. PubMed ID: 30101479
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of SRPK1, a key splicing regulator, exhibits antitumor and chemotherapeutic-sensitizing effects on extranodal NK/T-cell lymphoma cells.
He C; Liu B; Wang HY; Wu L; Zhao G; Huang C; Liu Y; Shan B; Liu L
BMC Cancer; 2022 Oct; 22(1):1100. PubMed ID: 36303126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
